HYLORIS PHARMACEUTICALS SA(EBR:HYL) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, HYL scores 4 out of 10 in our fundamental rating. HYL was compared to 53 industry peers in the Pharmaceuticals industry. While HYL seems to be doing ok healthwise, there are quite some concerns on its profitability. HYL shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HYL has reported negative net income.

In the past year HYL has reported a negative cash flow from operations.

In the past 5 years HYL always reported negative net income.

In the past 5 years HYL always reported negative operating cash flow.

1.2 Ratios

HYL's Return On Assets of -26.92% is on the low side compared to the rest of the industry. HYL is outperformed by 77.36% of its industry peers.

HYL's Return On Equity of -35.29% is on the low side compared to the rest of the industry. HYL is outperformed by 79.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.92%
ROE	-35.29%
ROIC	N/A

ROA(3y)-23.37%

ROA(5y)-35.37%

ROE(3y)-28.52%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HYL's Gross Margin of 96.95% is amongst the best of the industry. HYL outperforms 94.34% of its industry peers.

In the last couple of years the Gross Margin of HYL has grown nicely.

The Profit Margin and Operating Margin are not available for HYL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.95%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y77.3%

GM growth 5Y27.31%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.

HYL has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for HYL has been increased compared to 5 years ago.

Compared to 1 year ago, HYL has a worse debt to assets ratio.

2.2 Solvency

HYL has an Altman-Z score of 6.09. This indicates that HYL is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.09, HYL belongs to the best of the industry, outperforming 90.57% of the companies in the same industry.

HYL has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.

HYL's Debt to Equity ratio of 0.05 is amongst the best of the industry. HYL outperforms 86.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	6.09

ROIC/WACCN/A

WACC7.75%

2.3 Liquidity

HYL has a Current Ratio of 3.71. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.

HYL's Current ratio of 3.71 is amongst the best of the industry. HYL outperforms 94.34% of its industry peers.

HYL has a Quick Ratio of 3.71. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.

HYL has a Quick ratio of 3.71. This is amongst the best in the industry. HYL outperforms 98.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.71
Quick Ratio	3.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.55% over the past year.

The Revenue has grown by 235.54% in the past year. This is a very strong growth!

Measured over the past years, HYL shows a very strong growth in Revenue. The Revenue has been growing by 87.11% on average per year.

EPS 1Y (TTM)33.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.77%

Revenue 1Y (TTM)235.54%

Revenue growth 3Y128.47%

Revenue growth 5Y87.11%

Sales Q2Q%576.38%

3.2 Future

Based on estimates for the next years, HYL will show a very strong growth in Earnings Per Share. The EPS will grow by 47.94% on average per year.

HYL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.61% yearly.

EPS Next Y2.34%

EPS Next 2Y12.91%

EPS Next 3Y2.29%

EPS Next 5Y47.94%

Revenue Next Year65.48%

Revenue Next 2Y76.74%

Revenue Next 3Y80.54%

Revenue Next 5Y108.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HYL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year HYL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.91%

EPS Next 3Y2.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for HYL!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HYLORIS PHARMACEUTICALS SA

EBR:HYL (5/29/2025, 7:00:00 PM)

5.76

+0.08 (+1.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0.02%

Inst Owner ChangeN/A

Ins Owners56.62%

Ins Owner ChangeN/A

Market Cap161.28M

Analysts80

Price Target13.94 (142.01%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)7.33%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	31.75
P/FCF	N/A
P/OCF	N/A
P/B	4.65
P/tB	5.23
EV/EBITDA	N/A

EPS(TTM)-0.43

EYN/A

EPS(NY)-0.42

Fwd EYN/A

FCF(TTM)-0.45

FCFYN/A

OCF(TTM)-0.43

OCFYN/A

SpS0.18

BVpS1.24

TBVpS1.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.92%
ROE	-35.29%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	96.95%
FCFM	N/A

ROA(3y)-23.37%

ROA(5y)-35.37%

ROE(3y)-28.52%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y77.3%

GM growth 5Y27.31%

F-Score4

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	118.37%
Cap/Sales	11.42%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.71
Quick Ratio	3.71
Altman-Z	6.09

F-Score4

WACC7.75%

ROIC/WACCN/A

Cap/Depr(3y)455.46%

Cap/Depr(5y)302.17%

Cap/Sales(3y)50.77%

Cap/Sales(5y)371.99%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)33.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.77%

EPS Next Y2.34%

EPS Next 2Y12.91%

EPS Next 3Y2.29%

EPS Next 5Y47.94%

Revenue 1Y (TTM)235.54%

Revenue growth 3Y128.47%

Revenue growth 5Y87.11%

Sales Q2Q%576.38%

Revenue Next Year65.48%

Revenue Next 2Y76.74%

Revenue Next 3Y80.54%

Revenue Next 5Y108.61%

EBIT growth 1Y27.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.74%

EBIT Next 3Y32.72%

EBIT Next 5Y63.13%

FCF growth 1Y-32.75%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-43.57%

OCF growth 3YN/A

OCF growth 5YN/A

HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens